Company profile
Shanghai Huilun Pharmaceutical Co., Ltd.
Privately held: no public share price (Shanghai Yidian is described as a wholly-owned subsidiary of Shanghai Huilun Pharmaceutical Co., Ltd., a privately held Chinese API/small-molecule drug developer founded 2004; resolved to that parent, which has no stock listing found. Not on our roster. Sources: https://clinicaltrials.gov/study/NCT07159243 ; https://api.gleif.org/api/v1/lei-records/984500G84CRC0D4B3920 ; https://api.gleif.org/api/v1/lei-records/984500CE07P48BCA4D79 ; https://synapse.patsnap.com/organization/70c871364980c21abacb803835716eb1 ; https://www.huilunbio.com/?l=en-us Entity resolved by asset-pipeline-v2.)
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | —Small molecule | Diabetic Peripheral Neuropathic Pain |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.